Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/7830
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPatil, Prathamesh S.-
dc.contributor.authorSuryawanshi, Sushank J.-
dc.contributor.authorPatil, Sharvil S.-
dc.contributor.authorPawar, Atmaram P.-
dc.date.accessioned2024-11-12T01:46:47Z-
dc.date.available2024-11-12T01:46:47Z-
dc.date.issued2024-
dc.identifier.issn1658-3612-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/7830-
dc.description.abstractObjectives: Antibiotics are the most commonly administered medications among pediatric patients. However most of the time, accurate dose administration to children becomes a problem due to the extremely bitter taste. Cefpodoxime proxetil (CP) and roxithromycin (ROX) are antibiotics often prescribed to the pediatric population and have a bitter taste. Marketed formulations of these drugs are dry suspension and/or tablets. The lyophilization method involves various steps and thus is time consuming and expensive. The objective of this study was to mask the bitter taste of CP and ROX without compromising the solubility and drug release profile compared to marketed formulations, as well as to overcome the disadvantages associated with the currently used lyophilization technique. Methods: Hot melt extrusion (HME) technology was used to process CP and ROX individually with Eudragit E PO polymer. The extrudates obtained were characterized by Fourier transform infrared spectroscopy, powder X-ray diffraction, and differential scanning calorimetry. The powdered extrudates were formulated as dispersible tablets and evaluated for in vitro and in vivo tastemasking efficiency. Results: The tablets prepared in this study showed comparable dissolution profiles but the taste-masking efficiency was significantly enhanced compared to the marketed tablets of CP and ROX. The results of in vivo human taste-masking evaluation were also in agreement with the in vitro taste-masking studies. Conclusion: The current work presents solvent-free, scalable, and continuous HME technology for addressing the bitter taste issues of CP and ROX. The disadvantages associated with the currently used lyophilization technique were overcome by developing the formulations using HME technology.en_US
dc.language.isoen_USen_US
dc.publisherJournal of Taibah University Medical Sciencesen_US
dc.relation.ispartofseriesOriginal Article;252-262-
dc.subjectDispersible tabletsen_US
dc.subjectDissolutionen_US
dc.subjectEudragit EPOen_US
dc.subjectHot melt extrusionen_US
dc.subjectTaste maskingen_US
dc.titleHME-assisted formulation of taste-masked dispersible tablets of cefpodoxime proxetil and roxithromycinen_US
dc.typeArticleen_US
Appears in Collections:Vol 19 No 2 (2024)

Files in This Item:
File Description SizeFormat 
252-262.pdf2.26 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.